Literature DB >> 17398060

Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas.

G Garcea1, A R Dennison, S L Ong, C J Pattenden, C P Neal, C D Sutton, C D Mann, D P Berry.   

Abstract

AIMS: We have maintained a highly conservative policy in selecting patients with carcinoma of the head of pancreas for resection. This has been based on tumour size, evidence of lymph node involvement or local invasion outside of the gland at laparotomy, laparoscopy or CT imaging. This study investigated our survival rates following pancreatic resection and examined clinicopathological predictors of survival.
METHODS: Sixty-two consecutive patients undergoing pancreatic resections for malignancy were identified from 1999 onwards. Thirty-three underwent resection for pancreatic ductal adenocarcinoma and were included in our analysis, the remainder included resections for ampullary adenocarcinoma (n=20) or other malignancies (n=9). Patient, tumour and operative characteristics were analysed to assess predictors of survival following resection (Kaplan-Meier survival curves).
RESULTS: Median survival following resection for ductal pancreatic adenocarcinoma was 54 months (ampullary adenocarcinomas achieved a median survival of 62 months) and thirty-day mortality was 2.7% (n=1). Survival was not associated with any demographic or intraoperative factors, such as blood loss, operative duration or anaesthetic technique. Survival curves were significantly worse when perineural or vascular invasion was evident histologically (p=0.023 and 0.0023 respectively). Patients with positive lymph nodes had a significantly shorter survival (p=0.0030) especially when lymph node status was expressed as a percentage of total lymph node yield. If more than 20% of retrieved lymph nodes were positive for tumour, this was a clear predictor of survival (p<0.0001). A positive resection margin was also associated with shortened survival (p=0.0291).
CONCLUSION: Despite the advances made in the management of pancreatic cancer, tumour biology still dictates long-term survival. A highly selective surgical approach to the management of these patients results in good long-term survival.

Entities:  

Mesh:

Year:  2007        PMID: 17398060     DOI: 10.1016/j.ejso.2007.02.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  15 in total

Review 1.  Current treatment options for pancreatic carcinoma.

Authors:  Emily Castellanos; Jordan Berlin; Dana Backlund Cardin
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

Review 2.  Pathology handling of pancreatoduodenectomy specimens: Approaches and controversies.

Authors:  María Del Carmen Gómez-Mateo; Luis Sabater-Ortí; Antonio Ferrández-Izquierdo
Journal:  World J Gastrointest Oncol       Date:  2014-09-15

3.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

4.  Vascular invasion in infiltrating ductal adenocarcinoma of the pancreas can mimic pancreatic intraepithelial neoplasia: a histopathologic study of 209 cases.

Authors:  Seung-Mo Hong; Michael Goggins; Christopher L Wolfgang; Richard D Schulick; Barish H Edil; John L Cameron; Adriana Handra-Luca; Joseph M Herman; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

5.  Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.

Authors:  Edwina N Scott; Giuseppe Garcea; Helena Doucas; Will P Steward; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2009-03       Impact factor: 3.647

6.  Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Authors:  Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams
Journal:  Am J Clin Oncol       Date:  2018-12       Impact factor: 2.339

7.  The role of surgery for pancreatic cancer: a 12-year review of patient outcome.

Authors:  S A Badger; J L Brant; C Jones; J McClements; M B Loughrey; M A Taylor; T Diamond; L D McKie
Journal:  Ulster Med J       Date:  2010-05

8.  Preoperative defining system for pancreatic head cancer considering surgical resection.

Authors:  Seok Jeong Yang; Ho Kyoung Hwang; Chang Moo Kang; Woo Jung Lee
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

9.  Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.

Authors:  S L Ong; G Garcea; S C Thomasset; C D Mann; C P Neal; M Abu Amara; A R Dennison; D P Berry
Journal:  J Gastrointest Surg       Date:  2007-11-28       Impact factor: 3.452

10.  Pancreatic head carcinoma and vascular endothelial growth factor (VEGF-A) concentration in portal blood: its association with cancer grade, tumor size and probably poor prognosis.

Authors:  Piotr Hogendorf; Adam Durczyński; Anna Kumor; Janusz Strzelczyk
Journal:  Arch Med Sci       Date:  2014-05-13       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.